Mylan Generic Treads On AstraZeneca Patents, Fed. Circ. Hears

Law360, Washington (April 5, 2012, 4:09 PM EDT) -- Drugmaker AstraZeneca LP told the Federal Circuit on Thursday that a Delaware federal court had erred when it determined Mylan Pharmaceuticals Inc.'s generic version of Crohn's disease treatment Entocort EC didn't infringe two of the pharmaceutical giant's patents.

In June, the Delaware court ruled AstraZeneca hadn't done enough to prove Mylan's generic violated U.S. Patent Numbers 6,423,340 and 5,643,602. The patents cover a method and oral composition for the treatment of inflammatory bowel diseases, such as Crohn's disease.

AstraZeneca alleged Thursday that Mylan had misconstrued its...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.